On August 7, 2021, we searched these databases for the terms MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7, and “liver cancer.” The exposure group comprised LIHC patients, and the control group comprised normal patients (those with noncancerous liver tissue). This evidence concerns the gene MAP2K6 and liver cancer.